AzTrials
AzTrials

COPDNCT04997200

Effect of Sleep Deprivation on Breathlessness and Exercise Capacity in COPD

A study testing One night's sleeplessness in people with COPD, run by Skane University Hospital at 2 sites in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a randomized controlled cross-over trial designed to measure the effect of one night's sleep deprivation on exercise endurance, ventilation and breathlessness in outpatients with COPD. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COPD
What is being tested?
One night's sleeplessness
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
2 sitesSweden
Study dates
13 Sep 2021to 24 Oct 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18 years or older
  • COPD diagnosed by physician in accordance with Global Initiative For Chronic Obstructive Lung Disease (GOLD) guidelines (GOLD 2021), with a spirometric ratio of the forced expired volume in one second (FEV1) / forced vital capacity (FVC) < 0.7 and a FEV1 < 80% of predicted post bronchodilator at baseline.
  • Self-reported average sleep time of six hours or longer during a normal night.
  • No regular treatment with sleep medication or anxiolytics.
  • Able to cycle
  • Able to talk and write Swedish well enough to participate in the study procedures, as judged by the Investigator.

Who cannot join

  • Resting peripheral oxygen saturation (SpO2) < 92%
  • Night shift worker
  • Hospitalization or clinical instability during the last four weeks
  • Treatment with supplementary oxygen at rest or during exercise
  • Sleep disturbance, defined as a Pittsburgh Sleep Quality Index >5 at baseline
  • Contraindication to exercise testing in accordance with clinical practice guidelines (ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211-277)
  • Expected survival shorter than six months as judged by the Investigator.

Trial locations and contacts

2 sites in 1 country.

Sweden2 sites
  • Blekinge Tekniska Högskola (BTH)

    Karlskrona, Blekinge County, 37179

  • Department of Clinical Physiology, Blekinge Hospital

    Karlskrona, Blekinge County, SE-37185

Other trials in Sweden

About this study

Official title: Effect of Sleep Deprivation on Breathlessness and Exercise Capacity in COPD: a Randomized Crossover Trial

This is a randomized controlled cross-over trial designed to measure the effect of one night's sleep deprivation on exercise endurance, ventilation and breathlessness in outpatients with COPD.

Read the detailed description

Background:

Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality in the world. Breathlessness and exercise limitation are cardinal symptoms in COPD with grave consequences for the patient. Even with optimal COPD treatment a large number of these patients experience a breathlessness which limits their everyday life. Physical activity is the main trigger of breathlessness in daily life, but knowledge is limited on how other factors may affect exercise performance, breathing and exertional breathlessness in patients with COPD.

Sleep deprivation is common in the population in patients with COPD, and especially in patients with worsening health status and during hospitalizations. As many as 40-45% of patients older than 70 experience sleep deprivation during hospitalization. As many as 21 % of patients with COPD have a disturbed sleep. A recent study on healthy young males who breathed against an inspiratory resistance showed that one night's sleep deprivation significantly reduced their respiratory endurance and induced worse and more disturbing breathlessness.

Little is known how sleep loss affects patients with COPD in an outpatient setting. Several studies have evaluated the effect of sleep deprivation on exercise capacity in young healthy adults. However, very few studies have examined the effect of sleep deprivation on the exercise capacity or exertional breathlessness in patients with COPD; most data pertain to observational studies where no intervention took place and data from a randomized controlled trial (RCT) is needed. The presence of disturbed sleep in patients with COPD - and especially in relation to worsenings and hospitalizations, could have a marked detrimental effect on their breathing, increase suffering from distressing breathlessness and potentially increase the risk of adverse health outcomes and worse prognosis. Directed actions to improve sleeping in these settings could in that case improve the patients' outcomes.

Aim:

To test the effect of one sleepless night on breathlessness, exercise endurance and ventilation in patients with COPD.

Method:

This is a randomized (ratio 1:1), controlled, crossover trial of the effect of one night's sleep deprivation vs. normal sleep on exercise endurance, ventilation and breathlessness in outpatients with COPD. The study will not be blinded for participants and staff (due to the nature of the intervention) but will be blinded for the analyst.

The intervention is one night without sleep, and the control is one night with normal sleep. The test is a bicycle test (exercise test on a bike with continuous analysis of ventilation and gaseous exchange) carried out as a sub-max test at 75% of maximum capacity until the test person cannot go on.

The study consists of three visits. At the first visit, informed consent is collected, and inclusion and exclusion criteria are evaluated. Also, information is collected regarding the person's COPD-diagnosis, medication, and other illnesses. Specific surveys are Pittsburgh Sleep Quality Index (PSQI), COPD Assessment Test (CAT), modified Medical Research Council (mMRC) scale, 7-point Global Impression of Change (GIC) scale, Experienced sleep quality (Likert scale), Multidimensional Dyspnea Profile (MDP) to assess the person's sleep and respiration. Baseline values for dynamic spirometry, saturation, and blood pressure are also measured during the first visit. Afterwards, a bicycle test is carried out according to normal clinical standards. This involves increasing the resistance (in Watts) according to a set protocol until the test person is unable to continue. This takes roughly 6-10 minutes and provides a maximum performance value for the individual. This maximum value is used for visit number two and three. After this first visit the order of the sleepless night is randomized for either visit two or three.

At the second and third visit spirometry, saturation and blood pressure are once more measured. The person is evaluated for contraindications. Then a new bicycle test is carried out at 75% of the maximum W achieved at the first visit. The test takes around 10 minutes, and continues until the person is unable to continue. During this test, ventilation is measured as respiratory rate (RR), minute ventilation (MV), oxygen consumption (VO2), carbon dioxide consumption (VCO2), the respiratory quotient (VCO2/VO2), inspiratory capacity manoeuvre (IC), dynamic hyperinflation, ventilatory reserve capacity, ventilation efficiency (MV/VCO2-curve) and the anaerobic threshold. During the test the person is also assessed for how difficult the breathing feels (0-19 Borg CR10), how tired the legs feels (Borg CR10), how uncomfortable the breathing feels (mBorg 0-10) every two minutes and at the end of the test. At the end of the test the test person is asked about the reason for ending the test, how the breathing was experienced (Multidimensional Dyspnea Profile, MDP), and how motivated they were to carry out the test (0-10 NRS). The person is also monitored with EKG during the test, and the blood pressure is measured every two minutes. The results are then compared between the test where the person had a normal night's sleep, and the test where the person was awake the whole night before.

The normal night's sleep is assessed using some simple questions, such as: "How did you sleep tonight" and "How satisfied are you with the night's sleep?". It is also evaluated using an Actigraph bracelet that measures movement when worn. The bracelet is worn for 48 hours preceding both tests.

The night when the person is going to be awake is spent at the test lab, after eating a normal dinner at home. They then spend an entire night in a room where they can watch TV, use a phone or tablet or read books and magazines. They will be monitored by staff to help them stay awake during the night. They cannot eat, drink or smoke anything not usually consumed during the night (other than water). They then eat a normal breakfast of their choosing, and the test is carried out just like the one where they slept normally.

Conditions
COPD
Being tested
One night's sleeplessness
Keywords
Dyspnea, Respiration Disorders, Respiratory Tract Diseases, Signs and Symptoms, Respiratory
Medical subject headings
Pulmonary Disease, Chronic Obstructive, Dyspnea, Respiration Disorders, Respiratory Tract Diseases, Signs and Symptoms, Respiratory

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • One night's sleeplessnessBehavioural

    A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.

Study groups in NCT04997200
Study groupRoleWhat they receive
Intervention: One night's sleeplessnessExperimentalA night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test.
Receives: Behavioral: One night's sleeplessness
Control: One night's normal sleepNo interventionA normal night's sleep (at least six hours) in the patient's home.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in breathlessness intensity (Borg CR10) between control and intervention at iso-time

    Change between conditions in breathlessness intensity using the Borg Category Ratio scale (Borg CR10), where 0 indicates no exertion and 10 indicates maximum exertion, at iso-time (defined as the time of the latest similar time point during both conditions (control and intervention) during a constant rate cycle cardiopulmonary exercise test (CPET).

    Measured: Measured during post-control and post-intervention exercise tests, spaced 7 days to 6 weeks apart

Secondary outcomes (20)
  1. Change in breathlessness unpleasantness (Borg CR10) between control and intervention

    Perceived unpleasantness from breathlessness, measured with the Borg CR10 scale, where 0 indicates no exertion and 10 indicates maximum exertion. Compared at end exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  2. Change in time to the limit of tolerance (tLIM) between control and intervention

    For how long the test person can continue the test, measured in seconds.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  3. Change in oxygen consumption between control and intervention (absolute)

    Measured using 7V'O2 (aerobic exercise capacity), in absolute numbers. Compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  4. Change in oxygen consumption between control and intervention (%pred)

    Measured using V'O2, (aerobic exercise capacity), in percent of predicted (%pred). Compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  5. Change in workload (W) between control and intervention

    Maximum workload achieved, measured in Watts, in absolute numbers.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  6. Change in workload (%pred) between control and intervention

    Maximum workload achieved, measured in percent of predicted (%pred).

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  7. Change in Minute ventilation (VE) between control and intervention

    Minute ventilation is measured and compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  8. Change in tidal volume (VT) between control and intervention

    Tidal volume measured and compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  9. Change in ventilatory reserve, (MVV) - (VE) between control and intervention

    Ventilatory reserve defined as maximum voluntary ventilation (MVV) - (VE). Compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  10. Change in cardiac reserve between control and intervention

    Cardiac reserve is evaluated using the predicted peak heart rate. Compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  11. Change in dynamic hyperinflation and inspiratory capacity (IC) between control and intervention

    This includes measures of constrained ventilatory expansion such as the inspiratory reserve volume (IRV). Compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  12. Change in breathing frequency between control and intervention

    Breathing frequency is measured, and compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  13. Change in breathlessness intensity at peak exercise (Borg CR10) between control and intervention

    Perceived breathlessness intensity at peak exercise is evaluated using the Borg CR10 scale, where 0 indicates no exertion and 10 indicates maximum exertion, and compared between the tests.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  14. Change in leg discomfort (Borg CR10) between control and intervention

    Perceived leg discomfort is evaluated using the Borg CR10 scale, where 0 indicates no exertion and 10 indicates maximum exertion, and compared between the tests.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  15. Change in timing of the anaerobic threshold (AT) between control and intervention

    At the anaerobic threshold, timing is registered, and compared between the tests.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  16. Change in V'O2 of the anaerobic threshold (AT) between control and intervention

    At the anaerobic threshold, V'O2 is registered, and compared between the tests.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  17. Change in efficacy of ventilation (VE/V'CO2-slope and ratio at the AT) between control and intervention

    VE/V'CO2-slope and ratio are evaluated at the anaerobic threshold, and compared between the tests.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  18. Change in respiratory exchange ratio (RER), defined as V'CO2/V'O2 between control and intervention

    Respiratory exchange ratio is calculated using V'CO2/V'O2, and compared between the tests at peak exercise and at iso-time.

    Measured: Measured during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  19. Change in causes for stopping the test between control and intervention

    The test person's reason for discontinuing the test is recorded.

    Measured: Evaluated during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

  20. Change in any adverse events during the control and intervention tests

    Any adverse events during the tests are recorded.

    Measured: Evaluated during post-control and post-intervention tests, spaced 7 days to 6 weeks apart

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Aug 2021
  2. Study start13 Sep 2021
  3. Primary completion24 Oct 2024
  4. Study completion24 Oct 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Crossover
Model description
Performed in randomized order on two separate days, at least seven days apart and no more than six weeks apart. * Intervention: A night without sleep. No daytime sleeping the day before the test. Participants are observed by staff at the trial unit during the night before the test. * Control: Normal night's sleep (at least six hours of sleep) in the patient's home. The participants wear an actigraph during 48 hours before the test to ensure adherence to the allocated condition (sleep deprivation or control).
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04997200
Sponsor's protocol ID
Version 1
Status last verified
Apr 2026
First submitted
21 Jul 2021
Last updated
24 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • O'Donnell DE, Banzett RB, Carrieri-Kohlman V, Casaburi R, Davenport PW, Gandevia SC, Gelb AF, Mahler DA, Webb KA. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc. 2007 May;4(2):145-68. doi: 10.1513/pats.200611-159CC.

    PubMed 17494725
  • Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Mullerova H, Lomas DA, Wouters E, Bakke P, Rennard S, Crim C, Miller BE, Coxson HO, Yates JC, Tal-Singer R, Vestbo J; ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013 Sep;42(3):636-46. doi: 10.1183/09031936.00195212. Epub 2013 Jun 13.

    PubMed 23766334
  • Simon ST, Bausewein C, Schildmann E, Higginson IJ, Magnussen H, Scheve C, Ramsenthaler C. Episodic breathlessness in patients with advanced disease: a systematic review. J Pain Symptom Manage. 2013 Mar;45(3):561-78. doi: 10.1016/j.jpainsymman.2012.02.022. Epub 2012 Aug 24.

    PubMed 22921180
  • Dharmarajan K, Swami S, Gou RY, Jones RN, Inouye SK. Pathway from Delirium to Death: Potential In-Hospital Mediators of Excess Mortality. J Am Geriatr Soc. 2017 May;65(5):1026-1033. doi: 10.1111/jgs.14743. Epub 2016 Dec 30.

    PubMed 28039852
  • Rault C, Sangare A, Diaz V, Ragot S, Frat JP, Raux M, Similowski T, Robert R, Thille AW, Drouot X. Impact of Sleep Deprivation on Respiratory Motor Output and Endurance. A Physiological Study. Am J Respir Crit Care Med. 2020 Apr 15;201(8):976-983. doi: 10.1164/rccm.201904-0819OC.

    PubMed 31810378
  • Chen R, Tian JW, Zhou LQ, Chen X, Yan HY, Zeng B, Zhang MS. The relationship between sleep quality and functional exercise capacity in COPD. Clin Respir J. 2016 Jul;10(4):477-85. doi: 10.1111/crj.12249. Epub 2015 Jan 15.

    PubMed 25515647
  • Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010 Jun 1;152(11):726-32. doi: 10.7326/0003-4819-152-11-201006010-00232. Epub 2010 Mar 24.

    PubMed 20335313
  • Hedenstrom H, Malmberg P, Fridriksson HV. Reference values for lung function tests in men: regression equations with smoking variables. Ups J Med Sci. 1986;91(3):299-310. doi: 10.3109/03009738609178670.

    PubMed 3811032

Questions about this trial

What is this clinical trial studying?

A study testing One night's sleeplessness in people with COPD, run by Skane University Hospital at 2 sites in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in breathlessness intensity (Borg CR10) between control and intervention at iso-time (time frame: Measured during post-control and post-intervention exercise tests, spaced 7 days to 6 weeks apart). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04997200, which also lists 8 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in